OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Raoul Tibes Discusses FLT3 Inhibitors in AML

July 29th 2016

Impact of Precision Medicine in Refractory Malignancies

July 28th 2016

Maria Schwaederle, PharmD, Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, discusses results of a meta-analysis of 13,203 patients in phase I clinical trials.

Dr. Lancet on CPX-351 in Elderly Patients With AML

July 28th 2016

Jeffrey E. Lancet, MD, medical oncologist, Moffitt Cancer Center, discusses results of a randomized phase III study comparing the efficacy of CPX-351 (Vyxeos) versus daunorubicin (7+3) plus cytarabine in older patients with newly diagnosed, high-risk acute myeloid leukemia (AML).

Dr. Ma on the METRIC Trial in Triple-Negative Breast Cancer

July 28th 2016

Cynthia Ma, MD, PhD, associate professor of Medicine, Washington University School of Medicine, discusses the METRIC trial in triple-negative breast cancer.

Dr. Angela DeMichele on Selecting Best Therapies in TNBC

July 28th 2016

Dr. Max Topp on the TOWER study and Blinatumomab in ALL

July 28th 2016

Dr. Kaufman on Avelumab in Merkel Cell Carcinoma

July 28th 2016

Howard L. Kaufman, MD, chief surgical officer, associate director for clinical science, surgical oncologist, Rutgers Cancer Institute of New Jersey, discusses the phase II JAVELIN Merkel 200 study examining avelumab as a treatment for patients with Merkel cell carcinoma.

Dr. Arkenau on Advancements on Horizon in Gastric Cancer

July 27th 2016

Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, discusses immunotherapy advancements on the horizon in the field of gastric cancer.

Dr. Sparano on the Role of Endocrine Therapy in Breast Cancer

July 27th 2016

Joseph Sparano, MD, associate chairman, Clinical Research, Department of Oncology, Montefiore Medical Center, associate director, Clinical Research, Albert Einstein Cancer Center, discusses the ways in which the role of endocrine therapy has evolved over the years as a treatment for patients with breast cancer.

Dr. Stephanie Goff on Low-Dose Chemotherapy with CAR T-Cells in Advanced Lymphoma

July 27th 2016

Dr. Igor Aurer on Novel Treatments on the Horizon in Hodgkin Lymphoma

July 27th 2016

Dr. van den Bent on Adjuvant Temozolomide in Anaplastic Glioma

July 27th 2016

Martin J. Van Den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherland, discusses the results of an interim analysis of the randomized phase III CANTON trial, which investigated concurrent and adjuvant temozolomide in patients with anaplastic glioma without a 1p/19q co-deletion.

Dr. Abou-Alfa on Significance of RESORCE Trial for HCC

July 26th 2016

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma who progressed after receiving sorafenib (Nexavar).

Dr. DeAngelo on Inotuzumab Ozogamicin for Relapsed/Refractory ALL

July 26th 2016

Dr. Dang on the Significance of the MYL-1401O Biosimilar in HER2-Positive Metastatic Breast Cancer

July 26th 2016

Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the significance of MYL-1401O, a proposed biosimilar of trastuzumab, as a potential treatment for patients with HER2-positive metastatic breast cancer.

Dr. Tolcher on Utomilumab Plus Pembrolizumab in Advanced Solid Tumors

July 25th 2016

Anthony W. Tolcher, MD, director of clinical research at South Texas Accelerated Research Therapeutics San Antonio, discusses a phase Ib study examining the combination of the 4-1BB agonist utomilumab (PF-05082566) and pembrolizumab (Keytruda) as a treatment for patients with advanced solid tumors.

Dr. Younes Discusses FDA Approval of Nivolumab in Hodgkin Lymphoma

July 25th 2016

Anas Younes, MD, chief of the Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the impact of the FDA approval of nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma.

Dr. Finn on Regorafenib for the Treatment of Patients With HCC

July 25th 2016

Richard Finn, assistant professor of Medicine at the Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology at UCLA Jonsson Comprehensive Cancer Center, discusses regorafenib (Stivarga) for the treatment of patients with hepatocelluar carcinoma (HCC).

Dr. Van Cutsem on Regorafenib for Patients With Colorectal Cancer

July 25th 2016

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses regorafenib (Stivarga) as a treatment for patients with colorectal cancer.

Dr. Oh on Recognizing Symptom Burden in Advanced Prostate Cancer

July 22nd 2016

William K. Oh, MD, professor of Medicine, Hematology, and Medical Oncology, and Urology, Mount Sinai Hospital, discusses a global study aimed at recognizing symptom burden in patients with advanced prostate cancer.